Performance Milestone Payments. Licensee shall pay to Alliance the following performance milestone amounts:
Performance Milestone Payments. AbbVie shall make the payments set forth below in this Section 6.2 as additional consideration for the rights and licenses granted by Kadmon to AbbVie hereunder:
Performance Milestone Payments. THRESHOLD shall pay to BXXXXX ONCOLOGY the following one time amounts:
Performance Milestone Payments. [16] Licensee shall pay to University the following amounts upon the occurrence of the corresponding milestone: (a) Upon , Licensee shall pay to University $ ; (b) Upon , Licensee shall pay to University $ ; and (c) Upon , Licensee shall pay to University $ . Not applicable/none required. [16] Can be negotiated along with royalty rates and yearly fees.
Performance Milestone Payments. 11.9.1 Clinical Development Milestones: Text marked [****] has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested for the omitted information. Ø [****] upon dosing of the first human subject in a Phase I clinical trial of a Licensed Product; Ø [****] upon dosing of a first human subject in a Phase II clinical trial of a Licensed Product; Ø [****] upon dosing of a first human subject in a Phase III clinical trial of a Licensed Product; Ø [****] upon filing of an BLA with FDA (or EMEA or an equivalent authority in) in any jurisdiction, for a Licensed Product; Ø [****] following the first commercial sale of a Licensed Product; Ø [****] for the second commercial sale of a Licensed Product. Ø [****] for the first commercial sale of a Licensed Product for any non-human use.
Performance Milestone Payments. 11.9.1 Clinical Development Milestones: Ø $_______ upon dosing of the first human subject in a Phase I clinical trial of a Licensed Product; Ø $_______ upon dosing of a first human subject in a Phase II clinical trial of a Licensed Product; Ø $_______ upon dosing of a first human subject in a Phase III clinical trial of a Licensed Product; Ø $_______ upon filing of an BLA with FDA (or EMEA or an equivalent authority in) in any jurisdiction, for a Licensed Product; Ø $_______ following the first commercial sale of a Licensed Product; Ø $_______ for the second commercial sale of a Licensed Product. Ø $_______ for the first commercial sale of a Licensed Product for any non-human use.
Performance Milestone Payments. Aligos shall pay to Luxna the following non-refundable performance milestone amounts within [****] of the first achievement of each milestone listed below, whether triggered by actions of Aligos or an Affiliate or a Sublicensee, on a Licensed Compound-by-Licensed Compound basis. Milestone Milestone Payment (One Time Payments on a Per Licensed Compound/Licensed Product Basis) [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Milestone Milestone Payment (One Time Payments on a Per Licensed Compound/Licensed Product Basis) [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Aligos shall be obligated to make no more than one payment to Luxna for any one milestone, even if a milestone is achieved more than one time or in more than one jurisdiction.
Performance Milestone Payments. Licensee must pay to DUKE the non-refundable, non-creditable milestone payments set forth in Appendix A (hereafter, “Performance Milestone Fees”). Each Performance Milestone Fee is due and payable within 45 days of Licensee’s or sublicensee’s achievement of the relevant milestone.
Performance Milestone Payments. Subject to Section 5.3, SIGA will pay the following milestone payments with respect to the first discrete molecule which is a Licensed Product under the terms of this Agreement according to the following schedule:
Performance Milestone Payments. Neumora shall pay to Vanderbilt each of the following one-time only milestone payments for the occurrence of each respective milestone event, whether triggered by actions of Neumora or a Sublicensee or their Affiliates, at the time set forth in Paragraph 5.5.1.
